MYL, FRX And ACT, 3 Drugs Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 16,415 as of Thursday, April 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,581 issues advancing vs. 1,369 declining with 186 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is unchanged. A company within the industry that fell today was Shire ( SHPG), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Mylan ( MYL) is one of the companies pushing the Drugs industry lower today. As of noon trading, Mylan is down $1.02 (-2.2%) to $46.19 on light volume. Thus far, 2.1 million shares of Mylan exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $46.00-$47.13 after having opened the day at $47.01 as compared to the previous trading day's close of $47.21.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $17.2 billion and is part of the health care sector. Shares are up 8.8% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Forest Laboratories ( FRX) is down $0.98 (-1.1%) to $89.31 on light volume. Thus far, 590,430 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $89.00-$90.74 after having opened the day at $89.83 as compared to the previous trading day's close of $90.29.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $23.9 billion and is part of the health care sector. Shares are up 50.4% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Forest Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is down $3.01 (-1.5%) to $196.37 on light volume. Thus far, 819,990 shares of Actavis exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $195.37-$200.88 after having opened the day at $198.49 as compared to the previous trading day's close of $199.38.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $33.8 billion and is part of the health care sector. Shares are up 18.7% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists